Clinical Edge Journal Scan

Joint involvement starts earlier and more severely in hands than in feet in RA


 

Key clinical point: Functional disabilities involving the hands started earlier and were more frequent and severe than those involving feet in patients with clinically suspect arthralgia (CSA) who progressed toward rheumatoid arthritis (RA) or clinical inflammatory arthritis (IA).

Major finding: In patients with RA development, hand disabilities occurred earlier and were more frequent and severe (mean difference over time 0.41 units; P < .001) than foot disabilities. The evaluation of tender joints and subclinical joint inflammation showed similar findings for hand and foot involvement.

Study details: This study longitudinally assessed 600 patients with CSA who developed clinical IA or had at least 1 year of follow-up.

Disclosures: This study was supported by the European Research Council and the Dutch Arthritis Society. AHM van der Helm-van Mil declared being an Editorial Board Member for RMD Open. The other authors did not report any conflicts of interest.

Source: Khidir SJH et al. Joint involvement in RA starts predominantly in the hands: Functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA. RMD Open. 2023;9:e003107 (Jun 16). Doi: 10.1136/rmdopen-2023-003107

Recommended Reading

Ultrasound detects subclinical inflammation in RA patients with low or no disease activity
MDedge Rheumatology
Progressing joint damage: An indication to consider intensive treatment in RA patients in remission or LDA
MDedge Rheumatology
Sarcopenia prevalence and risk in older RA patients
MDedge Rheumatology
Methotrexate does not impair sperm quality, small study finds
MDedge Rheumatology
Commentary: DMARD and HCQ in RA, July 2023
MDedge Rheumatology
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
MDedge Rheumatology
Antidrug antibody effects compared across RA biologics
MDedge Rheumatology
Humira biosimilars: Five things to know
MDedge Rheumatology
Tofacitinib shows marginal edge over adalimumab in real-world patients with RA
MDedge Rheumatology
Certolizumab pegol and abatacept show superiority over conventional therapy in early RA
MDedge Rheumatology